Collegium Pharmaceutical COLL 2024 Investor Presentation

Collegium Pharmaceutical presents its September 2024 investor update, detailing the company's pharmaceutical portfolio, including Jornay PM and the recent Ironshore Therapeutics acquisition. The presentation covers financial guidance for 2024, adjusted EBITDA expectations, and the strategic impact of the acquisition on revenue growth and market positioning.